enlonstobart
mAbexperimental
Clinical trial activity
4 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started May 15, 2025 (NCT06981858)
Timeline
Indications
Mechanism of action
- Programmed cell death protein 1INHIBITOR
PDCD1 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5315040 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07288814 | Phase 1/Phase 2 (Phase 2) | Dec 8, 2025 | Sun Yat-Sen University, Yiling Pharmaceutical Inc. |
| NCT07254585 | Phase 2 | Dec 1, 2025 | Shijiazhuang Pharma Group (CSPC) |
| NCT06998771 | Phase 2 | Jun 15, 2025 | Shanghai JMT-Bio Inc. |
| NCT06981858 | Phase 2 | May 15, 2025 | Chongqing Medical University |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Chongqing Medical University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Shanghai JMT-Bio Inc. | For profit | 1 | 1 | 1 | 2025 |
| Shijiazhuang Pharma Group (CSPC) | For profit | 1 | 1 | 1 | 2025 |
| Sun Yat-Sen University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Yiling Pharmaceutical Inc. | For profit | 1 | 0 | 1 | 2025 |
5 organizations
Page 1 / 1